Barisoni L , et al.. A proposed taxonomy for the podocytopathies: A reassessment of the primary nephrotic diseases. Clin J Am Soc Nephrol 2007; 2:529−542. doi: 10.2215/CJN.04121206

• PubMed
Barisoni L , . A proposed taxonomy for the podocytopathies: A reassessment of the primary nephrotic diseases. Clin J Am Soc Nephrol 2007; 2:529−542. doi: 10.2215/CJN.04121206 )| false
• Search Google Scholar
• Export Citation

Garin EH , et al.. Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney Int 2010; 78:296−302. doi: 10.1038/ki.2010.143

• PubMed
Garin EH , . Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney Int 2010; 78:296−302. doi: 10.1038/ki.2010.143 )| false
• Search Google Scholar
• Export Citation

Clement LC , et al.. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med 2011; 17:117−122. doi: 10.1038/nm.2261

• PubMed
Clement LC , . Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med 2011; 17:117−122. doi: 10.1038/nm.2261 )| false
• Search Google Scholar
• Export Citation

Kopp JB , et al.. Clinical features and histology of apolipoprotein L1-associated nephropathy in the FSGS Clinical Trial. J Am Soc Nephrol 2015; 26:1443−1448. doi: 10.1681/ASN.2013111242

• PubMed
Kopp JB , . Clinical features and histology of apolipoprotein L1-associated nephropathy in the FSGS Clinical Trial. J Am Soc Nephrol 2015; 26:1443−1448. doi: 10.1681/ASN.2013111242 )| false
• Search Google Scholar
• Export Citation

Landini S , et al.. Reverse phenotyping after whole-exome sequencing in steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2020; 15:89−100. doi: 10.2215/CJN.06060519

• PubMed
Landini S , . Reverse phenotyping after whole-exome sequencing in steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2020; 15:89−100. doi: 10.2215/CJN.06060519 )| false
• Search Google Scholar
• Export Citation

Black DA , et al.. Controlled trial of prednisone in adult patients with the nephrotic syndrome. Br Med J 1970; 3:421−426. doi: 10.1136/bmj.3.5720.421

• PubMed
Black DA , . Controlled trial of prednisone in adult patients with the nephrotic syndrome. Br Med J 1970; 3:421−426. doi: 10.1136/bmj.3.5720.421 )| false
• Search Google Scholar
• Export Citation

Coggins CH . Adult minimal change nephropathy: Experience of the collaborative study of glomerular disease. Trans Am Clin Climatol Assoc 1986; 97:18−26. PMID: 3915841

• PubMed
Coggins CH . Adult minimal change nephropathy: Experience of the collaborative study of glomerular disease. Trans Am Clin Climatol Assoc 1986; 97:18−26. PMID: 3915841 )| false
• Search Google Scholar
• Export Citation

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2012; 2:139−274. https://www.sciencedirect.com/journal/kidney-international-supplements/vol/2/issue/2

• PubMed
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2012; 2:139−274. https://www.sciencedirect.com/journal/kidney-international-supplements/vol/2/issue/2 )| false
• Search Google Scholar
• Export Citation

Li X , et al.. Tacrolimus monotherapy after intravenous methylprednisolone in adults with minimal change nephrotic syndrome. J Am Soc Nephrol 2017; 28:1286−1295. doi: 10.1681/ASN.2016030342

• PubMed
Li X , . Tacrolimus monotherapy after intravenous methylprednisolone in adults with minimal change nephrotic syndrome. J Am Soc Nephrol 2017; 28:1286−1295. doi: 10.1681/ASN.2016030342 )| false
• Search Google Scholar
• Export Citation

Patil MR , et al.. Tacrolimus as the first-line agent in adult-onset minimal change disease: A randomized controlled study. Saudi J Kidney Dis Transpl 2019; 30:129−137. https://www.sjkdt.org/article.asp?issn=1319-2442;year=2019;volume=30;issue=1;spage=129;epage=137;aulast=Patil

• PubMed
Patil MR , . Tacrolimus as the first-line agent in adult-onset minimal change disease: A randomized controlled study. Saudi J Kidney Dis Transpl 2019; 30:129−137. https://www.sjkdt.org/article.asp?issn=1319-2442;year=2019;volume=30;issue=1;spage=129;epage=137;aulast=Patil )| false
• Search Google Scholar
• Export Citation

Medjeral-Thomas NR , et al.. Randomized, controlled trial of tacrolimus and prednisolone monotherapy for adults with de novo minimal change disease: A multicenter, randomized, controlled trial. Clin J Am Soc Nephrol 2020; 15:209−218. doi: 10.2215/CJN.06180519

• PubMed
Medjeral-Thomas NR , . Randomized, controlled trial of tacrolimus and prednisolone monotherapy for adults with de novo minimal change disease: A multicenter, randomized, controlled trial. Clin J Am Soc Nephrol 2020; 15:209−218. doi: 10.2215/CJN.06180519 )| false
• Search Google Scholar
• Export Citation

Chin HJ , et al.. Comparison of the efficacy and safety of tacrolimus and low-dose corticosteroid with high-dose corticosteroid for minimal change nephrotic syndrome in adults. J Am Soc Nephrol 2021; 32:199−210. doi: 10.1681/ASN.2019050546

• PubMed
Chin HJ , . Comparison of the efficacy and safety of tacrolimus and low-dose corticosteroid with high-dose corticosteroid for minimal change nephrotic syndrome in adults. J Am Soc Nephrol 2021; 32:199−210. doi: 10.1681/ASN.2019050546 )| false
• Search Google Scholar
• Export Citation

Rémy P , et al.. An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study). Kidney Int 2018; 94:1217−1226. doi: 10.1016/j.kint.2018.07.021

• PubMed
Rémy P , . An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study). Kidney Int 2018; 94:1217−1226. doi: 10.1016/j.kint.2018.07.021 )| false
• Search Google Scholar
• Export Citation

Trachtman H , et al.. DUET: A phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J Am Soc Nephrol 2018; 29:2745−2754. doi: 10.1681/ASN.2018010091

• PubMed
Trachtman H , . DUET: A phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J Am Soc Nephrol 2018; 29:2745−2754. doi: 10.1681/ASN.2018010091 )| false
• Search Google Scholar
• Export Citation

Basu B , et al.. Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: A randomized clinical trial. JAMA Pediatr 2018; 172:757−764. doi: 10.1001/jamapediatrics.2018.1323

• PubMed
Basu B , . Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: A randomized clinical trial. JAMA Pediatr 2018; 172:757−764. doi: 10.1001/jamapediatrics.2018.1323 )| false
• Search Google Scholar
• Export Citation

Gauckler P , et al.. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis—what is known and what is still unknown? Autoimmun Rev 2020; 19:102671. doi: 10.1016/j.autrev.2020.102671

• PubMed
Gauckler P , . Rituximab in adult minimal change disease and focal segmental glomerulosclerosis—what is known and what is still unknown? Autoimmun Rev 2020; 19:102671. doi: 10.1016/j.autrev.2020.102671 )| false
• Search Google Scholar
• Export Citation

Büscher AK , et al.. Rapid response to cyclosporin A and favorable renal outcome in nongenetic versus genetic steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2016; 11:245−253. doi: 10.2215/CJN.07370715

• PubMed
Büscher AK , . Rapid response to cyclosporin A and favorable renal outcome in nongenetic versus genetic steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2016; 11:245−253. doi: 10.2215/CJN.07370715 )| false
• Search Google Scholar
• Export Citation

De Vriese AS , et al.. Differentiating primary, genetic, and secondary FSGS in adults: A clinicopathologic approach. J Am Soc Nephrol 2018; 29:759−774. doi: 10.1681/ASN.2017090958

• PubMed
De Vriese AS , . Differentiating primary, genetic, and secondary FSGS in adults: A clinicopathologic approach. J Am Soc Nephrol 2018; 29:759−774. doi: 10.1681/ASN.2017090958 )| false
• Search Google Scholar
• Export Citation